PARTNERSHIP OPPORTUNITIES
Free Shipping in the U.S. for orders over $1000. Shop Now>>
CD47, also known as integrin-associated protein (IAP), is a transmembrane protein encoded by the CD47 gene on chromosome 3q13.12. It consists of approximately 323 amino acids with a molecular weight of approximately 50–60 kDa. CD47 undergoes various post-translational modifications, including phosphorylation, glycosylation, and disulfide bond formation, contributing to its diverse functions as a critical regulator of immune responses, cell adhesion, and signaling. The primary function of CD47 is to serve as a “don’t eat me” signal by interacting with its receptor, signal regulatory protein alpha (SIRPα), on phagocytic cells such as macrophages. This interaction inhibits phagocytosis and prevents the clearance of cells expressing CD47, thus promoting immune evasion and maintaining immune homeostasis.
CD47 is expressed in a wide range of tissues and cell types, including hematopoietic, endothelial, epithelial, and neuronal cells. Its expression levels can vary between different cell types and tissues and are regulated by various factors, including cytokines, growth factors, and cellular signaling pathways. Its dysregulation is frequently observed in various cancers, including leukemia, lymphoma, breast cancer, and ovarian cancer, among others, suggesting its potential diagnostic and prognostic significance in these diseases. Elevated CD47 expression has been associated with tumor progression, aggressive behavior, increased metastasis, and poorer survival rates in certain cancer types, indicating its potential as both a diagnostic marker and a prognostic indicator for patient outcomes. Beyond cancer, dysregulated CD47 expression has also been implicated in autoimmune disorders, neurodegenerative diseases, and cardiovascular diseases, suggesting broader diagnostic and prognostic implications across different pathological conditions.
Furthermore, CD47 has emerged as a promising therapeutic target for cancer immunotherapy. One notable example is magrolimab (formerly known as Hu5F9-G4), a humanized monoclonal antibody designed to block the CD47-SIRPα interaction, thus promoting the phagocytosis of cancer cells by macrophages. Clinical trials have shown promising results for magrolimab in various hematologic malignancies like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Additionally, TTI-621 (SIRPαFc), a recombinant fusion protein acting as a decoy receptor for CD47, is being evaluated in clinical trials for hematologic malignancies and solid tumors.
NeoBiotechnologies offers a variety of antibodies against CD47 that have been validated for ELISA, flow cytometry, immunofluorescence, immunohistochemistry, and Western blotting. Additionally, we hold exclusive rights to CD47 antibodies available for licensing or collaboration [https://www.neobiotechnologies.com/gene-name/cd47/].
Leukocyte surface antigen CD47, Antigenic surface determinant protein OA3, Integrin-associated protein, Protein MER6, Antigenic Surface Determinant Protein OA3; IAP; Integrin Associated Protein; Integrin Associated Signal Transducer; MER6; OA3; Protein MER6; Rh Related Antigen
Showing all 11 results
Showing all 11 results
